帕博利珠单抗联合二甲双胍治疗转移性头颈部癌的 II 期可行性研究
A Phase II Feasibility Study Combining Pembrolizumab and Metformin in Patients with Metastatic Head and Neck Cancer.
二甲双胍联合帕博利珠单抗耐受性良好,仅出现轻度胃肠道不良事件,并展现出有前景的活性,值得在随机试验中进一步研究。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Epithelial YPEL3 Modulates CD8(+) T-Cell Infiltration and Tumor Progression Through CREB1-CXCL16 Signaling in HNSCC.
Epithelial YPEL3 Modulates CD8(+) T-Cell Infiltration and Tumor Progression Through CREB1-CXCL16 Signaling in HNSCC.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
Yippee样蛋白3(YPEL3)被认为参与调节多种癌症中的细胞凋亡、增殖和侵袭,但其在头颈部鳞状细胞癌(HNSCC)中的作用尚不清楚。
本研究整合泛癌数据、TCGA/GEO转录组、DNA甲基化谱和单细胞RNA测序,探究YPEL3在HNSCC中的表达、预后和免疫相关性。YPEL3在肿瘤组织中下调,并与较好的总生存期相关,晚期患者中尤为明显。功能实验确认,体外YPEL3可抑制增殖、迁移和侵袭,同时促进细胞凋亡;敲低YPEL3则加速体内肿瘤生长。整体转录组和TIMER分析显示,YPEL3高表达与基质及免疫浸润增加相关,包括CD8⁺ T细胞浸润。单细胞分析鉴定出富集YPEL3的上皮细胞亚群(Epi.C3),该亚群在肿瘤中扩增并与不良预后相关。
从机制上看,YPEL3高表达的上皮细胞分泌CXCL16,与CD8⁺ T细胞上的CXCR6相互作用,促进免疫参与。YPEL3通过CREB1而非TFAP2C调节CXCL16。共培养实验显示,上皮细胞YPEL3可调节T细胞中的CXCL16-CXCR6轴。体内YPEL3缺失与CD8⁺ T细胞浸润减少及其效应功能受损相关,表现为颗粒酶B、穿孔素、IFN-γ和TNF-α降低。
总体而言,这些发现确认YPEL3是肿瘤抑制因子,也是HNSCC中上皮-免疫相互作用的重要介质;它通过CREB1/CXCL16/CXCR6轴,将上皮分化相关状态与抗肿瘤免疫联系起来。
Yippee-like 3 (YPEL3) has been implicated in the regulation of apoptosis, proliferation, and invasion in various cancers, but its role in head and neck squamous cell carcinoma (HNSCC) remains unclear.
Here, we integrated pan-cancer data, TCGA/GEO transcriptomes, DNA methylation profiles, and single-cell RNA sequencing to explore YPEL3's expression, prognosis, and immune relevance in HNSCC. YPEL3 was downregulated in tumor tissues and correlated with better overall survival, particularly in advanced-stage patients.
Functional assays confirmed that YPEL3 suppressed proliferation, migration, and invasion while promoting apoptosis in vitro; its knockdown accelerated tumor growth in vivo. Bulk transcriptomics and TIMER analysis revealed that high YPEL3 expression was associated with increased stromal and immune infiltration, including CD8 + T cells. Single-cell analysis identified an epithelial subcluster (Epi. C3) enriched for YPEL3, expanded in tumors, and linked to poor prognosis.
Mechanistically, YPEL3-high epithelial cells secreted CXCL16, interacting with CXCR6 on CD8 + T cells to promote immune engagement. YPEL3 regulated CXCL16 via CREB1 but not TFAP2C. Co-culture assays showed that epithelial YPEL3 modulated the CXCL16-CXCR6 axis in T cells. In vivo, YPEL3 loss was associated with reduced CD8 + T-cell infiltration and impaired CD8 + T-cell effector function, as indicated by decreased Granzyme B, Perforin, IFN-γ, and TNF-α.
Together, these findings identify YPEL3 as a tumor suppressor and an important mediator of epithelial-immune crosstalk in HNSCC, linking epithelial differentiation-associated states to antitumor immunity through the CREB1/CXCL16/CXCR6 axis.
在 PubMed 查看 → 出版商原文(DOI) 全文 PDF(PMC)· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。